Investors Purchase Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of some unusual options trading on Monday. Stock traders purchased 9,455 call options on the company. This represents an increase of 146% compared to the average daily volume of 3,838 call options.

SELLAS Life Sciences Group Stock Performance

Shares of SLS traded down $0.10 during mid-day trading on Monday, reaching $1.53. The stock had a trading volume of 6,611,913 shares, compared to its average volume of 5,073,241. The business has a fifty day moving average of $1.05 and a 200 day moving average of $1.17. The firm has a market cap of $107.33 million, a price-to-earnings ratio of -2.22 and a beta of 2.42. SELLAS Life Sciences Group has a 12 month low of $0.56 and a 12 month high of $1.84.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new stake in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $39,000. XTX Topco Ltd purchased a new stake in shares of SELLAS Life Sciences Group during the 3rd quarter valued at $78,000. Virtu Financial LLC boosted its holdings in SELLAS Life Sciences Group by 24.1% in the third quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock worth $99,000 after acquiring an additional 15,398 shares in the last quarter. State Street Corp increased its stake in SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after purchasing an additional 40,500 shares in the last quarter. Finally, Opus Capital Group LLC grew its stake in SELLAS Life Sciences Group by 5.5% during the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company’s stock valued at $248,000 after purchasing an additional 12,400 shares during the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.